参考文献/References:
[1] Burns KEA, Rizvi L, Cook DJ, et al. Ventilator weaning and discontinuation practices for critically ill patients[J]. JAMA,2021, 325(12): 1173-1184.
[2] Vanhorebeek I, Latronico N. Van den Berghe G. ICU-acquired weakness[J]. Intensive Care Med, 2020, 46(4): 637-653.
[3] Doherty N, Steen CD. Critical illness polyneuromyopathy(CIPNM); rehabilitation during critical illness. Therapeutic options in nursing to promote recovery: a review of the literature[J]. Intensive Crit Care Nurs, 2010, 26(6): 353-362.
[4] Dalton RE, Tripathi RS, Abel EE, et al. Polyneuropathy and myopathy in the elderly[J]. HSR Proc Intensive Care Cardiovasc Anesth, 2012, 4(1): 15-19.
[5] Puthucheary ZA, Rawal J, McPhail M, et al. Acute skeletal muscle wasting in critical illness[J]. JAMA, 2013, 310(15): 1591-1600.
[6] Su Y, Yuki M, Otsuki M. Prevalence of stroke-related sarcopenia: a systematic review and meta-analysis[J]. J Stroke Cerebrovasc Dis, 2020, 29(9): 105092.
[7] Rieu I, Balage M, Sornet C, et al. Leucine supplementation improves muscle protein synthesis in elderly men independently of hyperaminoacidaemia[J]. J Physiol, 2006, 575(Pt 1): 305-315.
[8] Anthony JC, Anthony TG, Kimball SR, et al. Signaling pathways involved in translational control of protein synthesis in skeletal muscle by leucine[J]. J Nutr, 2001, 131(3): 856S-860S.
[9] Wilson GJ, Wilson JM, Manninen AH. Effects of beta-hydroxybeta-methylbutyrate (HMB) on exercise performance and body composition across varying levels of age, sex, and training experience: a review[J]. Nutr Metab (Lond), 2008, 5: 1.
[10] Ikeda K, Takahashi M, Aburaya S, et al. Produced β-hydroxybutyrate after β -hydroxy- β -methylbutyrate (HMB) administration may contribute HMB function in mice[J].Biochem Biophys Rep, 2021, 27: 101097.
[11] 田 林, 陈锦瑶. β-羟基-β-甲基丁酸钙安全性和有效性研究进展[J]. 食品安全质量检测学报, 2021, 12(16): 6565-6572.
[12] Kuriyan R, Lokesh DP, Selvam S, et al. The relationship of endogenous plasma concentrations of β -hydroxy β -methyl butyrate (HMB) to age and total appendicular lean mass in humans[J]. Exp Gerontol, 2016, 81: 13-18.
[13] Fitschen PJ, Wilson GJ, Wilson JM, et al. Efficacy of β-hydroxy-β-methylbutyrate supplementation in elderly and clinical populations[J]. Nutrition, 2013, 29(1): 29-36.
[14] Hsieh LC, Chien SL, Huang MS, et al. Anti-inflammatory and anticatabolic effects of short-term beta-hydroxy-betamethylbutyrate supplementation on chronic obstructive pulmonary disease patients in intensive care unit[J]. Asia Pac J Clin Nutr, 2006, 15(4): 544-550.
[15] Wilkinson DJ, Hossain T, Hill DS, et al. Effects of leucine and its metabolite β -hydroxy- β -methylbutyrate on human skeletal muscle protein metabolism[J]. J Physiol, 2013, 591(11): 2911-2923.
[16] Schwartz AL, Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases[J]. Annu Rev Med, 1999, 50:57-74.
[17] Zheng J, Li B, Yan YT, et al. β -hydroxy- β -methylbutyric acid promotes repair of sheep myoblast injury by inhibiting IL-17/NF-κB signaling[J]. Int J Mol Sci, 2022, 24(1): 444.
[18] Zhang Y, Yang M, Zhou P, et al. β -hydroxy- β -methylbutyrateInduced upregulation of miR-199a-3p contributes to slow-to-fast muscle fiber type conversion in mice and C2C12 cells[J]. J Agric Food Chem, 2020, 68(2): 530-540.
[19] Eley HL, Russell ST, Baxter JH, et al. Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response tocachectic stimuli[J]. Am J Physiol Endocrinol Metab, 2007, 293(4): E923-E931.
[20] Hole?ek M. Beta-hydroxy-beta-methylbutyrate supplementation and skeletal muscle in healthy and muscle-wasting conditions[J]. J Cachexia Sarcopenia Muscle, 2017, 8(4): 529-541.
[21] Patel P, Butani K, Kumar A, et al. Effects of fermented food consumption on non-communicable diseases[J]. Foods, 2023, 12(4): 687.
[22] Picca A, Ponziani FR, Calvani R, et al. Gut microbial, inflammatory and metabolic signatures in older people with physical frailty and sarcopenia: results from the BIOSPHERE study[J]. Nutrients, 2019, 12(1): 65.
[23] Zheng P, Zeng B, Zhou C, et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism[J]. Mol Psychiatry, 2016, 21(6): 786-796.
[24] Picca A, Fanelli F, Calvani R, et al. Gut dysbiosis and muscle aging: searching for novel targets against sarcopenia[J]. Mediators Inflamm, 2018, 2018: 7026198.
[25] Bindels LB, Delzenne NM. Muscle wasting: the gut microbiota as a new therapeutic target?[J]. Int J Biochem Cell Biol, 2013, 45(10): 2186-2190.
[26] Locantore P, Del Gatto V, Gelli S, et al. The interplay between immune system and microbiota in osteoporosis[J]. Mediators Inflamm, 2020, 2020: 3686749.
[27] 石培洁, 冯 健, 胡 健, 等. 基于“肠-肌轴”的营养干预在ICU获得性衰弱治疗的研究进展[J]. 肠外与肠内营养, 2023, 30(4):249-253.
[28] 唐玉秀, 韦 瑶, 金 钧. 肠-肺轴以及粪菌移植在脓毒症中的作用[J]. 肠外与肠内营养, 2023, 30(3): 179-184.
[29] Duan YH, Zhong YZ, Xiao H, et al. Gut microbiota mediates the protective effects of dietary β-hydroxy-β-methylbutyrate (HMB) against obesity induced by high-fat diets[J]. FASEB J, 2019, 33(9): 10019-10033.
[30] Frampton J, Murphy KG, Frost G, et al. Short-chain fatty acids as potential regulators of skeletal muscle metabolism and function[J]. Nat Metab, 2020, 2(9): 840-848.
[31] Tang G, Du Y, Guan HC, et al. Butyrate ameliorates skeletal muscle atrophy in diabetic nephropathy by enhancing gut barrier function and FFA2-mediated PI3K/Akt/mTOR signals[J]. Br JPharmacol, 2022, 179(1): 159-178.
[32] Chen FY, Li Q, Chen Y, et al. Association of the gut microbiota and fecal short-chain fatty acids with skeletal muscle mass and strength in children[J]. FASEB J, 2022, 36(1): e22109.
[33] Cryan JF, O’Riordan KJ, Cowan CSM, et al. The microbiota-gut-brain axis[J]. Physiol Rev, 2019, 99(4): 1877-2013.
[34] 冯莉娟, 李子纯, 刘小伟. 肠道菌群-肠-脑轴的研究进展[J]. 中华消化杂志, 2022, 42(2): 134-136.
[35] Kumar A, Pramanik J, Goyal N, et al. Gut microbiota in anxiety and depression: unveiling the relationships and management options[J]. Pharmaceuticals (Basel), 2023, 16(4): 565.
[36] Vendrik KEW, Ooijevaar RE, de Jong PRC, et al. Fecal microbiota transplantation in neurological disorders[J]. Front Cell Infect Microbiol, 2020, 10: 98.
[37] Miramonti AA, Stout JR, Fukuda DH, et al. Effects of 4 weeks of High-Intensity interval training and β -hydroxy- β -methylbutyric free acid supplementation on the onset of neuromuscular fatigue[J]. J Strength Cond Res, 2016, 30(3): 626-634.
[38] Salto R, Vílchez JD, Girón MD, et al. β -hydroxy- β-methylbutyrate (HMB) promotes neurite outgrowth in neuro2a cells[J]. PLoS One, 2015, 10(8): e0135614.
[39] Kougias DG, Nolan SO, Koss WA, et al. Beta-hydroxy-betamethylbutyrate ameliorates aging effects in the dendritic tree of pyramidal neurons in the medial prefrontal cortex of both maleand female rats[J]. Neurobiol Aging, 2016, 40: 78-85.
[40] Paidi RK, Raha S, Roy A, et al. Muscle-building supplement β-hydroxy β -methylbutyrate binds to PPARα to improve hippocampal functions in mice[J]. Cell Rep, 2023, 42(7): 112717.
[41] Hankosky ER, Sherrill LK, Ruvola LA, et al. Effects of β-hydroxy- β -methyl butyrate on working memory and cognitive flexibility in an animal model of aging[J]. Nutr Neurosci, 2017,20(7): 379-387.
[42] Nissen S, Sharp RL, Panton L, et al. Beta-hydroxy-betamethylbutyrate (HMB) supplementation in humans is safe and may decrease cardiovascular risk factors[J]. J Nutr, 2000, 130(8):1937-1945.
[43] Alway SE, Pereira SL, Edens NK, et al. β -Hydroxy- β-methylbutyrate (HMB) enhances the proliferation of satellite cells in fast muscles of aged rats during recovery from disuse atrophy[J]. Exp Gerontol, 2013, 48(9): 973-984.
[44] Sarto F, Franchi MV, McPhee JS, et al. Neuromuscular impairment at different stages of human sarcopenia[J]. J Cachexia Sarcopenia Muscle, 2024, 15(5): 1797-1810.
[45] Supinski GS, Netzel PF, Westgate PM, et al. A randomized controlled trial to determine whether beta-hydroxy-betamethylbutyrate and/or eicosapentaenoic acid improves diaphragm and quadriceps strength in critically Ill mechanically ventilated patients[J]. Crit Care, 2021, 25(1): 308.
[46] Wu TT, Li CX, Zhuang YN, et al. Resistance training combined with β-hydroxy β-methylbutyrate for patients with critical illness: a four-arm, mixed-methods, feasibility randomised controlled trial [J]. Intensive Crit Care Nurs, 2024, 82: 103616.
[47] Wu TT, Chen QL, Lin XX, et al. Effects of a multilevel intervention of resistance training with or without beta-hydroxybeta-methylbutyrate in medical ICU patients during entire hospitalisation: a four-arm multicentre randomised controlled trial[J]. Crit Care, 2023, 27(1): 493.
[48] Deutz NE, Matheson EM, Matarese LE, et al. Readmission and mortality in malnourished, older, hospitalized adults treated with a specialized oral nutritional supplement: a randomized clinical trial[J]. Clin Nutr, 2016, 35(1): 18-26.
[49] Landi F, Calvani R, Picca A, et al. Beta-hydroxy-betamethylbutyrate and sarcopenia: from biological plausibility to clinical evidence[J]. Curr Opin Clin Nutr Metab Care, 2019, 22 (1): 37-43.
[50] Liu SM, Zhang L, Li SQ. Advances in nutritional supplementation for sarcopenia management[J]. Front Nutr, 2023,10: 1189522.
[51] Wilson JM, Fitschen PJ, Campbell B, et al. International society of sports nutrition position stand: beta-hydroxy-betamethylbutyrate (HMB)[J]. J Int Soc Sports Nutr, 2013, 10(1): 6.
[52] Wandrag L, Brett SJ, Frost G, et al. Impact of supplementation with amino acids or their metabolites on muscle wasting in patients with critical illness or other muscle wasting illness: a systematic review[J]. J Hum Nutr Diet, 2015, 28(4): 313-330.
[53] Viana MV, Becce F, Pantet O, et al. Impact of β -hydroxy- β-methylbutyrate (HMB) on muscle loss and protein metabolism in critically ill patients: a RCT[J]. Clin Nutr, 2021, 40(8): 4878-4887.
[54] Wittholz K, Fetterplace K, Karahalios A, et al. Beta-hydroxy-betamethylbutyrate supplementation and functional outcomes in multitrauma patients: a pilot randomized controlled trial[J]. JPENJ Parenter Enteral Nutr, 2023, 47(8): 983-992.